Atossa Therapeutics Inc (ATOS) Stock Price, Quote & News

Company Profile

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 588 0256

Website: www.atossatherapeutics.com

Address:

448 NW Market Street, Suite 500, Seattle, United States

dcajic2 Aug. 19 at 4:32 PM

$ATOS the only way this stock goes higher is with a buyout from one of the bigger medical companies. It just seems that this company is all about collecting big pay checks and going it alone.

0 · Reply

RichardDangler Aug. 19 at 4:31 PM

$ATOS big money rotation into bio sector after $MRNA news. ATOS could benefit greatly if the upcoming phase 2 trials all post good results.

0 · Reply

dcajic2 Aug. 19 at 4:31 PM

$ATOS shorted again. This is getting silly. Nothing pre than a phase 2 company that will not get data for another few months. In reality do you really think the data is Going to be good? Reality is they need to do a Much bigger phase 2 study that hasn’t even started yet.

0 · Reply

Kittyc803 Aug. 19 at 2:48 PM

$ATOS

0 · Reply

DateNightMike Aug. 19 at 2:42 PM

$ATOS $MRNA ATOS is next.

1 · Reply

DHern924 Aug. 19 at 2:37 PM

$ATOS there you go!!

0 · Reply

Cheffinance Aug. 19 at 1:16 PM

$ATOS squay need to do other 9 little pump and dump to pay holidays for their

0 · Reply

Cheffinance Aug. 19 at 1:10 PM

$ATOS crazy volume

0 · Reply

NOYES Aug. 19 at 1:04 PM

$ATOS i doubt quay is thinking on Mrna cancer vaccines???

0 · Reply

DCalcote Aug. 19 at 12:30 PM

$ATOS ...

0 · Reply

Atossa Therapeutics reports Q2 EPS (95c) vs. (98c) last year

Aug 7, 2026, 8:45 AM EDT - 12 days ago

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Aug 7, 2026, 7:00 AM EDT - 12 days ago

Atossa Therapeutics Quarterly report: Q2 2026

Aug 7, 2026, 7:00 AM EDT - 12 days ago

Atossa Therapeutics Earnings release: Q2 2026

2026-07-30T17:05:56.000Z - 20 days ago

Atossa Therapeutics sees opportunities for (Z)-endoxifen beyond breast cancer

2026-07-30T17:05:28.000Z - 20 days ago

Meet Atossa Therapeutics: Fly Exclusive with CFO Mark Daniel

2026-07-28T12:36:10.000Z - 22 days ago

Atossa Therapeutics’ (Z)-endoxifen compounds show anti-breast cancer action

Jul 28, 2026, 8:30 AM EDT - 22 days ago

Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer

Jul 21, 2026, 8:30 AM EDT - 4 weeks ago

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

2026-07-07T12:15:16.000Z - 6 weeks ago

Atossa Therapeutics initiated with a Buy at Rodman & Renshaw

Jun 12, 2026, 5:30 PM EDT - 2 months ago

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

2026-06-11T12:07:04.000Z - 2 months ago

Atossa Therapeutics announces registered direct offering of up to $16.5M

2026-06-11T12:06:50.000Z - 2 months ago

Atossa Therapeutics announces $16.5M registered direct offering

Jun 11, 2026, 8:00 AM EDT - 2 months ago

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

May 27, 2026, 8:30 AM EDT - 3 months ago

Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial

May 20, 2026, 4:45 PM EDT - 3 months ago

Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

May 19, 2026, 4:00 PM EDT - 3 months ago

Atossa Therapeutics Transcript: Status update

May 14, 2026, 8:30 AM EDT - 3 months ago

Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer

2026-05-08T16:29:20.000Z - 3 months ago

Atossa Therapeutics reports Q1 EPS ($1.11) vs. (78c) last year

May 8, 2026, 8:45 AM EDT - 3 months ago

Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

May 8, 2026, 7:00 AM EDT - 3 months ago

Atossa Therapeutics Quarterly report: Q1 2026

May 8, 2026, 7:00 AM EDT - 3 months ago

Atossa Therapeutics Earnings release: Q1 2026

2026-05-07T05:43:04.000Z - 3 months ago

Atossa Therapeutics’ Endoxifen shows breast cancer risk prevention in trial

May 6, 2026, 8:30 AM EDT - 3 months ago

Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women

2026-05-04T13:09:59.000Z - 3 months ago

Atossa Therapeutics says FDA grants RPD to (Z)-endoxifen to treat MAS

May 4, 2026, 8:30 AM EDT - 3 months ago

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome

Mar 30, 2026, 8:00 AM EDT - 5 months ago

Atossa Therapeutics Proxy statement: Proxy filing

2026-03-26T11:21:53.000Z - 5 months ago

Atossa Therapeutics target adjusted to $25 from $7 at H.C. Wainwright

2026-03-25T21:40:26.000Z - 5 months ago

Atossa Therapeutics reports 2025 EPS ($4.04), consensus ($3.91)

Mar 25, 2026, 5:30 PM EDT - 5 months ago

Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update

Mar 25, 2026, 7:00 AM EDT - 5 months ago

Atossa Therapeutics Earnings release: Q4 2025

Mar 25, 2026, 7:00 AM EDT - 5 months ago

Atossa Therapeutics Annual report: Q4 2025

Mar 20, 2026, 8:00 AM EDT - 5 months ago

Atossa Therapeutics Proxy statement: Proxy filing

2026-03-19T12:07:12.000Z - 5 months ago

Atossa Therapeutics announces addition of two biopharma executives to team

Mar 19, 2026, 8:00 AM EDT - 5 months ago

Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives

Mar 12, 2026, 8:00 AM EDT - 5 months ago

Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference

2026-02-12T14:20:21.000Z - 6 months ago

Atossa Therapeutics price target lowered to $10 from $35 at Craig-Hallum

Feb 11, 2026, 8:30 AM EST - 6 months ago

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook

Feb 11, 2026, 6:00 AM EST - 6 months ago

Atossa Therapeutics Slides: Corporate presentation

Feb 5, 2026, 8:30 AM EST - 6 months ago

Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program

Jan 21, 2026, 9:05 AM EST - 7 months ago

Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025

Jan 16, 2026, 4:40 PM EST - 7 months ago

Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy

Jan 6, 2026, 8:15 AM EST - 8 months ago

Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer

Dec 22, 2025, 7:00 AM EST - 8 months ago

Atossa Therapeutics Proxy statement: Proxy Filing

Dec 17, 2025, 8:15 AM EST - 8 months ago

Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category

Dec 15, 2025, 8:00 AM EST - 8 months ago

Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium

Dec 12, 2025, 7:00 AM EST - 8 months ago

Atossa Therapeutics Proxy statement: Proxy Filing

Dec 11, 2025, 8:00 AM EST - 8 months ago

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy

Dec 9, 2025, 8:00 AM EST - 9 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen

Dec 4, 2025, 8:00 AM EST - 9 months ago

Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum

Dec 2, 2025, 8:00 AM EST - 9 months ago

Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma

Nov 17, 2025, 9:07 AM EST - 9 months ago

Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation

Nov 12, 2025, 8:30 AM EST - 10 months ago

Atossa Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 8:30 AM EST - 10 months ago

Atossa Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 8:15 AM EST - 10 months ago

Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Nov 6, 2025, 8:00 AM EST - 10 months ago

Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium

Oct 21, 2025, 8:00 AM EDT - 10 months ago

Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents

Oct 15, 2025, 8:00 AM EDT - 11 months ago

Atossa Therapeutics to Present at the Maxim Growth Summit 2025

Oct 14, 2025, 8:00 AM EDT - 11 months ago

Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness

Oct 13, 2025, 8:00 AM EDT - 11 months ago

Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals

Oct 6, 2025, 8:00 AM EDT - 11 months ago

Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities

Oct 1, 2025, 8:30 AM EDT - 11 months ago

Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones

Sep 17, 2025, 8:00 AM EDT - 1 year ago

Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services

Sep 8, 2025, 3:00 PM EDT - 1 year ago

Atossa Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction

Aug 28, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference

Aug 20, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Earnings release: Q2 2025

Jul 29, 2025, 7:45 AM EDT - 1 year ago

Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer

Jun 5, 2025, 8:10 AM EDT - 1 year ago

Atossa Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 8:45 AM EDT - 1 year ago

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

May 22, 2025, 4:15 PM EDT - 1 year ago

Atossa Therapeutics Transcript: Status Update

May 20, 2025, 9:00 AM EDT - 1 year ago

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

May 14, 2025, 8:15 AM EDT - 1 year ago

Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen

May 13, 2025, 8:00 AM EDT - 1 year ago

Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

May 12, 2025, 6:00 PM EDT - 1 year ago

Atossa Therapeutics Earnings release: Q1 2025

May 12, 2025, 6:00 PM EDT - 1 year ago

Atossa Therapeutics Quarterly report: Q1 2025

Apr 30, 2025, 8:45 AM EDT - 1 year ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

Apr 29, 2025, 8:45 AM EDT - 1 year ago

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

Apr 22, 2025, 8:45 AM EDT - 1 year ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Atossa Therapeutics Proxy statement: Proxy Filing

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Earnings Call Transcript: Q4 2024

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Earnings release: Q4 2024

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Annual report: Q4 2024

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Slides: Q4 2024

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Mar 20, 2025, 9:13 AM EDT - 1 year ago

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

dcajic2 Aug. 19 at 4:32 PM

$ATOS the only way this stock goes higher is with a buyout from one of the bigger medical companies. It just seems that this company is all about collecting big pay checks and going it alone.

0 · Reply

RichardDangler Aug. 19 at 4:31 PM

$ATOS big money rotation into bio sector after $MRNA news. ATOS could benefit greatly if the upcoming phase 2 trials all post good results.

0 · Reply

dcajic2 Aug. 19 at 4:31 PM

0 · Reply

Kittyc803 Aug. 19 at 2:48 PM

$ATOS

0 · Reply

DateNightMike Aug. 19 at 2:42 PM

$ATOS $MRNA ATOS is next.

1 · Reply

DHern924 Aug. 19 at 2:37 PM

$ATOS there you go!!

0 · Reply

Cheffinance Aug. 19 at 1:16 PM

$ATOS squay need to do other 9 little pump and dump to pay holidays for their

0 · Reply

Cheffinance Aug. 19 at 1:10 PM

$ATOS crazy volume

0 · Reply

NOYES Aug. 19 at 1:04 PM

$ATOS i doubt quay is thinking on Mrna cancer vaccines???

0 · Reply

DCalcote Aug. 19 at 12:30 PM

$ATOS ...

0 · Reply

DHern924 Aug. 19 at 11:36 AM

$ATOS do you see $MRNA ? Do that

0 · Reply

Bunster Aug. 18 at 4:48 PM

$ATOS bad luck reverse split happened feb 2 6 and half months ago. pps trading day b4 it 9.00 and now 2.60. same bulls then same bulls now . same bulls when pps was at 20dollars same bulls now... But the smart ones left. The mr ripleys the night owl the 7 11s the pom pom boys and scores of others. even bull michael parks alias patent decision NO WORRIES left. even the bs the bulls here ate up when pompom boy and others said quay is working on covid not on atos. WAS IT MJP WHO SAID QUAY WORKS 18 HOURS A DAY AND ALL COVID WORK IS ON HIS OWN TIME NOT ON ATOSES. AM I ACCURATE THERE?.

0 · Reply

Bunster Aug. 18 at 4:02 PM

$ATOS IS THE RIGHTEST POSTER HERE DCAJ GOOD OR LUCKY. EVERY TIME SHE SHORTS MORE pps goes down . every time stock goes up to 18c pre rs bulls get excited and come out and post talking nonsense its 18c not 88c not 76c not 65c not 45c but 18 pennies.

0 · Reply

TheChangedBear Aug. 18 at 2:30 PM

$ATOS Dumpster begging for the DICKie again😆😅🤣😂

1 · Reply

Bunster Aug. 18 at 2:08 PM

$ATOS keep watching bulls primeis in control of this pos pps today dickie watch every tick if i want ot to go up i do one thing and if i want it to go down a do another.. GET SOME FRESH AIR DICKIE. TODAY PRIME IS THE PERSON OF HONOR

0 · Reply

dcajic2 Aug. 18 at 1:54 PM

$ATOS another good short. Survival For this company is a dream.

0 · Reply

Chalutz Aug. 17 at 11:26 PM

$ATOS Even if Quay gets the job I doubt he would be required to start Monday? They have an acting Director. Is Quay qualified for the position? Is RFK qualified to be head of NIH and Quay’s boss? DYOR and MYODS but no way I’m missing this sitting at $25 mil market cap and potential catalysts 2nd half of year. Not investment advice. GLTA!

0 · Reply

samirsss Aug. 17 at 11:22 PM

$ATOS I do expect Evangeline trial data by End of August or early September. That should be a good catalyst for the stock to go up and then we drop the I-SPY2 data followed by Karisma durability data before end of September as well. This should give a decent boost

1 · Reply

ALDERAANandON Aug. 17 at 11:04 PM

$ATOS Hello Everyone. Last time I wrote in February I said I was stepping away for a while but keeping my remaining position invested for lack of any better strategy. Today's (7.31%!) gain today and some of the immediate reaction inspired me to take a page from @Bunster's playbook: a 19-cent gain is equivalent to a 1.26-cent gain pre RS. There is no early boarding on the Hype Train.

0 · Reply

DHern924 Aug. 17 at 10:07 PM

$ATOS wtf😅

0 · Reply

Bunster Aug. 17 at 8:28 PM

$ATOS HOW SOON???? TODN. BURN YOUR CHARTS!!!!NOW

0 · Reply

todn Aug. 17 at 8:19 PM

$ATOS need to close the last gap @4.40

0 · Reply

Market Cap	27.84M
Revenue (ttm)	0.00
Net Income (ttm)	-34.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	53,206
Avg Vol	182,486
Day's Range	N/A - N/A
Shares Out	9.98M
Stochastic %K	48%
Beta	1.29
Analysts	Strong Sell
Price Target	$19.50